Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...
A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...
Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...
Moment of Clarity is pleased to offer TMS treatment. Moment of Clarity highlights Transcranial Magnetic Stimulation (TMS) as a safe, non-invasive treatment for depression, anxiety, and other mental ...
Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...
Multiple sclerosis (MS) is a chronic autoimmune disease affecting more than 2.9 million people worldwide. It occurs when the ...
3don MSN
Polymer scaffold can self-assemble in tissue to deliver multiple vaccine components over time
Sometimes, the best way to achieve a big outcome is to start small. That principle is at the center of new work from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback